MiR-152 suppresses the proliferation and invasion of NSCLC cells by inhibiting FGF2

Experimental and Molecular Medicine

Volumn 46, Issue 8, 2014, Pages

  Cheng, Zhenshun ^a   Ma, Rongli ^b   Tan, Weijun ^a   Zhang, Li ^a  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; MICRORNA; MICRORNA 152; UNCLASSIFIED DRUG; MIRN152 MICRORNA, HUMAN;

ADULT; ARTICLE; CANCER CELL; CANCER THERAPY; CANCER TISSUE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MALE; CELL MOTION; GENE EXPRESSION REGULATION; GENETICS; LUNG; LUNG TUMOR; METABOLISM; MIDDLE AGED; NON SMALL CELL LUNG CANCER; PATHOLOGY; TUMOR INVASION;

CARCINOMA, NON-SMALL-CELL LUNG; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM INVASIVENESS;

EID: 84927930807     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/emm.2014.51     Document Type: Article

References (37)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L et al. Recent cancer survival in Europe: A 2000-02 period analysis of EUROCARE- 4 data. Lancet Oncol 2007; 8: 784-796.
3. Daniels MG, Bowman RV, Yang IA, Govindan R, Fong KM. An emerging place for lung cancer genomics in 2013. J Thorac Dis 2013; 5 (Suppl 5), S491-S497.
4. Chou J, Shahi P, Werb Z. microRNA-mediated regulation of the tumor microenvironment. Cell Cycle 2013; 12: 3262-3271.
5. Hu J, Fang Y, Cao Y, Qin R, Chen Q. miR-449a regulates proliferation and chemosensitivity to cisplatin by targeting cyclin D1 and BCL2 in SGC7901 cells. Dig Dis Sci 2014; 59: 336-345.
6. Alrfaei BM, Vemuganti R, Kuo JS. microRNA-100 targets SMRT/NCOR2, reduces proliferation, and improves survival in glioblastoma animal models. PLoS ONE 2013; 8: e80865.
7. Ke Y, Zhao W, Xiong J, Cao R. Downregulation of miR-16 promotes growth and motility by targeting HDGF in non-small cell lung cancer cells. FEBS Lett 2013; 587: 3153-3157.
8. Xin C, Zhang H, Liu Z. miR-154 suppresses colorectal cancer cell growth and motility by targeting TLR2. Mol Cell Biochem 2014; 387: 271-277.
9. Liu Y, Li M, Zhang G, Pang Z. MicroRNA-10b overexpression promotes nonsmall cell lung cancer cell proliferation and invasion. Eur J Med Res 2013; 18: 41.
10. Zhang N, Wei X, Xu L. miR-150 promotes the proliferation of lung cancer cells by targeting P53. FEBS Lett 2013; 587: 2346-2351.
11. Lei L, Huang Y, Gong W. miR-205 promotes the growth, metastasis and chemoresistance of NSCLC cells by targeting PTEN. Oncol Rep 2013; 30: 2897-2902.
12. Nian W, Ao X, Wu Y, Huang Y, Shao J, Wang Y et al. miR-223 functions as a potent tumor suppressor of the Lewis lung carcinoma cell line by targeting insulin-like growth factor-1 receptor and cyclin-dependent kinase 2. Oncol Lett 2013; 6: 359-366.
13. Yuan Y, Shen Y, Xue L, Fan H. miR-140 suppresses tumor growth and metastasis of non-small cell lung cancer by targeting insulin-like growth factor 1 receptor. PLoS ONE 2013; 8: e73604.
14. Sanfiorenzo C, Ilie MI, Belaid A, Barlesi F, Mouroux J, Marquette CH et al. Two panels of plasma microRNAs as non-invasive biomarkers for prediction of recurrence in resectable NSCLC. PLoS ONE 2013; 8: e54596.
15. Zhu C, Li J, Ding Q, Cheng G, Zhou H, Tao L et al. miR-152 controls migration and invasive potential by targeting TGFalpha in prostate cancer cell lines. Prostate 2013; 73: 1082-1089.
16. Zheng X, Chopp M, Lu Y, Buller B, Jiang F. MiR-15b and miR-152 reduce glioma cell invasion and angiogenesis via NRP-2 and MMP-3. Cancer Lett 2013; 329: 146-154.
17. Tsuruta T, Kozaki K, Uesugi A, Furuta M, Hirasawa A, Imoto I et al. miR-152 is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer. Cancer Res 2011; 71: 6450-6462.
18. Su Y, Wang Y, Zhou H, Lei L, Xu L. MicroRNA-152 targets ADAM17 to suppress NSCLC progression. FEBS Lett 2014; 588: 1983-1988.
19. Chira P, Vareli K, Sainis I, Papandreou C, Briasoulis E. Alterations of microRNAs in solid cancers and their prognostic value. Cancers 2010; 2: 1328-1353.
20. Shen Y, Tang D, Yao R, Wang M, Wang Y, Yao Y et al. microRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation. Med Oncol 2013; 30: 750.
21. Bi Y, Han Y, Bi H, Gao F, Wang X. miR-137 impairs the proliferative and migratory capacity of human non-small cell lung cancer cells by targeting paxillin. Hum Cell 2014; 27: 95-102.
22. Lei L, Huang Y, Gong W. Inhibition of miR-92b suppresses nonsmall cell lung cancer cells growth and motility by targeting RECK. Mol Cell Biochem 2014; 387: 171-176.
23. Chen Y, Song YX, Wang ZN. The microRNA-148/152 family: multi-faceted players. Mol Cancer 2013; 12: 43.
24. Azizi M, Teimoori-Toolabi L, Arzanani MK, Azadmanesh K, Fard-Esfahani P, Zeinali S. MicroRNA-148b and microRNA-152 reactivate tumor suppressor genes through suppression of DNA methyltransferase-1 gene in pancreatic cancer cell lines. Cancer Biol Ther 2014; 15: 419-427.
25. Xiang Y, Ma N, Wang D, Zhang Y, Zhou J, Wu G et al. MiR-152 and miR- 185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: A novel epigenetic therapy independent of decitabine. Oncogene 2014; 33: 378-386.
26. Ji W, Yang L, Yuan J, Yang L, Zhang M, Qi D et al. MicroRNA-152 targets DNA methyltransferase 1 in NiS-transformed cells via a feedback mechanism. Carcinogenesis 2013; 34: 446-453.
27. Xu Q, Jiang Y, Yin Y, Li Q, He J, Jing Y et al. A regulatory circuit of miR-148a/152 and DNMT1 in modulating cell transformation and tumor angiogenesis through IGF-IR and IRS1. J Mol Cell Biol 2013; 5: 3-13.
28. Huang J, Wang Y, Guo Y, Sun S. Down-regulated microRNA-152 induces aberrant DNA methylation in hepatitis B virus-related hepatocellular carcinoma by targeting DNA methyltransferase 1. Hepatology 2010; 52: 60-70.
29. Farhat FS, Tfayli A, Fakhruddin N, Mahfouz R, Otrock ZK, Alameddine RS et al. Expression, prognostic and predictive impact of VEGF and bFGF in non-small cell lung cancer. Crit Rev Oncol/Hematol 2012; 84: 149-160.
30. Polnaszek N, Kwabi-Addo B, Peterson LE, Ozen M, Greenberg NM, Ortega S et al. Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer. Cancer Res 2003; 63: 5754-5760.
31. Berger W, Setinek U, Mohr T, Kindas-Mugge I, Vetterlein M, Dekan G et al. Evidence for a role of FGF-2 and FGF receptors in the proliferation of non-small cell lung cancer cells. Int J Cancer 1999; 83: 415-423.
32. Lau MT, So WK, Leung PC. Fibroblast growth factor 2 induces E-cadherin down-regulation via PI3K/Akt/mTOR and MAPK/ERK signaling in ovarian cancer cells. PLoS ONE 2013; 8: e59083.
33. Barclay C, Li AW, Geldenhuys L, Baguma-Nibasheka M, Porter GA, Veugelers PJ et al. Basic fibroblast growth factor (FGF-2) overexpression is a risk factor for esophageal cancer recurrence and reduced survival, which is ameliorated by coexpression of the FGF-2 antisense gene. Clin Cancer Res 2005; 11: 7683-7691.
34. Coleman SJ, Chioni AM, Ghallab M, Anderson RK, Lemoine NR, Kocher HM et al. Nuclear translocation of FGFR1 and FGF2 in pancreatic stellate cells facilitates pancreatic cancer cell invasion. EMBO Mol Med 2014; 6: 467-481.
35. Rades D, Seibold ND, Gebhard MP, Noack F, Bruchhage KL, Schild SE. Fibroblast growth factor 2 is of prognostic value for patients with locally advanced squamous cell carcinoma of the head and neck. Strahlenther Onkol 2014; 190: 68-74.
36. Zhou B, Ma R, Si W, Li S, Xu Y, Tu X et al. MicroRNA-503 targets FGF2 and VEGFA and inhibits tumor angiogenesis and growth. Cancer Lett 2013; 333: 159-169.
37. Fons P, Gueguen-Dorbes G, Herault JP, Geronimi F, Tuyaret J, Frederique D et al. Tumor vasculature is regulated by FGF/FGFR signaling-mediated angiogenesis and bone marrow-derived cell recruitment: This mechanism is inhibited by SSR128129E, the first allosteric antagonist of FGFRs. J Cell Physiol 2014 (e-pub ahead of print 24 April 2014; doi:10.1002/jcp.24656).